New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
04:55 EDTNVDQ, NVDQ, NVDQ, MMSI, MMSI, MMSI, TEAR, TEAR, TEAR, ABAX, ABAX, ABAX, ELGX, ELGX, ELGX, VASC, VASC, VASCLazard to hold a conference
6th Annual MedTech, Diagnostics & Healthcare IT Snowbird Conference is being held in Snowbird, Utah on March 18-20.
News For NVDQ;MMSI;TEAR;ABAX;ELGX;VASC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
10:35 EDTMMSIMerit Medical to host conference call
Conference call to discuss agreement to acquire HeROGraft from CryoLife, Inc. will be held on February 4 at 11 am. Webcast Link
10:01 EDTABAXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at DA Davidson... Abaxis (ABAX) initiated with an Underperform at Credit Suisse... Aratana Therapeutics (PETX) initiated with an Outperform at Credit Suisse... Care.com (CRCM) initiated with an Equal Weight at Morgan Stanley... GCP Applied Technologies (GCP) initiated with a Buy at Jefferies... Heritage-Crystal Clean (HCCI) initiated with a Buy at Roth Capital... IDEXX (IDXX) initiated with an Outperform at Credit Suisse... Nexvet Biopharma (NVET) initiated with an Outperform at Credit Suisse... PetMed Express (PETS) initiated with an Underperform at Credit Suisse... Phibro Animal Health (PAHC) initiated with an Outperform at Credit Suisse... Pure Storage (PSTG) initiated with a Perform at Oppenheimer... SeaWorld (SEAS) initiated with a Neutral at Janney Capital... Seattle Genetics (SGEN) initiated with an Overweight at Barclays... VCA Inc. (WOOF) initiated with an Outperform at Credit Suisse... Verizon (VZ) initiated with a Neutral at DA Davidson... Zoetis (ZTS) initiated with an Outperform at Credit Suisse.
09:06 EDTMMSIMerit Medical acquires HeRO Graft from CryoLife for $18.5M
Subscribe for More Information
08:16 EDTMMSICryoLife sells HeRO graft to Merit Medical for $18.5M
Subscribe for More Information
07:44 EDTABAXAbaxis initiated with an Underperform at Credit Suisse
Credit Suisse analyst Erin Wilson initiated Abaxis with an Unperform rating and $39 price target on shares. Wilson sees slowing growth, increasing competition, and reduced contributions from new distribution relationships pressuring earnings growth.
February 3, 2016
16:03 EDTELGXEndologix completes merger with TriVascular Technologies
Subscribe for More Information
February 1, 2016
07:21 EDTTEARTearLab files to sell $15M in common stock
Subscribe for More Information
07:06 EDTTEARTearLab sees FY16 revenue growth 20% growth, consensus $32.19M
TearLab anticipates that it will maintain a 20 plus percent year-over-year revenue growth rate in 2016. This may be positively impacted by a number of potential growth accelerators, such as a regulatory approvals and commercial launch for TearLab's next generation multiplex tear testing platform, increased international market development, and the addition of osmolarity testing to professional clinical practice guidelines and protocols, some of which may occur during 2016. Over the longer-term, the productivity of its installed base should help the gross margins for the osmolarity testing business increase from the approximate 50% level achieved today to up to 60%. TearLab believes the combination of revenue growth, improving gross margins and disciplined cost control would allow it to achieve positive cash flow from operations when its annual revenue reaches a range of $50M to $60M.
07:05 EDTTEARTearLab to initiate divestiture or orderly wind down of OcuHub
TearLab announced that, based on a strategic review of its business, it has made a decision to initiate a divestiture or orderly wind down of its majority owned OcuHub subsidiary.While TearLab continues to explore a possible sale of OcuHub, if a divestiture transaction does not materialize, the wind down of the OcuHub operations is expected to be completed by the end of the first quarter of 2016. TearLab expects to record a pre-tax charge of approximately $1.4M related to the impairment of intangibles and fixed assets, which will be recorded in the fourth quarter of 2015. In addition, in the event of a wind down of the OcuHub business, TearLab expects to record an estimated pre-tax restructuring charge of approximately $600K for expenses related to winding down the business in the first quarter of 2016. However, the final restructuring charge and actual cost of winding down the business may vary significantly depending on the final disposition of OcuHub.
07:04 EDTTEARTearLab 'makes progress' towards introducing multiplex testing platform
Subscribe for More Information
07:02 EDTTEARTearLab sees FY15 revenue $25.2M, consensus $25.35M
In addition, the company estimates its available cash balance at December 31, 2015 to be $13.8M.
07:02 EDTTEARTearLab sees Q4 revenue $6.8M, consensus $6.9M
Subscribe for More Information
January 28, 2016
16:04 EDTABAXAbaxis reports Q3 EPS 35c, consensus 33c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use